Veracyte Launches $100 Million Buyback, Narrows 2026 Revenue Outlook
Veracyte narrowed its fiscal 2026 revenue guidance to $590 million-$593 million from $590 million-$596 million. It lowered expected annual Decipher Prostate test volume growth to 12,000-15,000 from approximately 20,000, citing market normalization and increased competition.
Alongside its third-quarter earnings report, Veracyte announced a new $100 million share buyback program. The company also narrowed its fiscal 2026 revenue guidance to a range of $590 million to $593 million, down from its previous forecast of $590 million to $596 million. The revision follows weaker-than-expected volume growth for its Decipher Prostate test, with the company lowering its annual Decipher volume growth expectations to 12,000—15,000 tests from approximately 20,000, citing market normalization and increased competition.